Related Experiment Videos
[New agents and challenges in the antithrombotic management of arterial diseases]
Insights
Antithrombotic therapy faces challenges in preventing blood clots after heart attack and stroke. New agents and combined treatments show promise for improving outcomes and preventing reocclusion.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Context:
- Antithrombotic therapy, including anticoagulants, antiplatelet agents, and fibrinolytics, has encountered significant challenges.
- Myocardial infarction reperfusion requires improved fibrinolytic agents and combined anticoagulant-antiplatelet strategies.
- Secondary stroke prevention necessitates updated thrombolytic and anticoagulant approaches.
Purpose:
- To address the evolving challenges in antithrombotic therapy.
- To highlight the need for improved treatments for myocardial infarction and stroke.
- To explore advancements in antithrombotic agents and their administration.
Summary:
- Reocclusion and restenosis of coronary arteries remain critical issues in antithrombotic treatment.
- Development of novel agents like disintegrins, monoclonal antibodies, hirudin analogs, and new-generation thrombolytics has been accelerated.
- Combined and sequential administration of diverse antithrombotic agents is gaining attention and shows promise.
Impact:
- Advances in antithrombotic therapy aim to improve patient outcomes in cardiovascular and cerebrovascular diseases.
- Novel therapeutic strategies are being developed to combat challenging conditions like reocclusion and restenosis.
- The evolving landscape of antithrombotic treatment offers new hope for secondary prevention and management of thrombotic events.
Abstract:
The past decades have exposed and faced antithrombotic therapy (anticoagulants, antiplatelet agents, and fibrinolytics) to new challenges. The reperfusion treatment modalities of myocardial infarction needed improvement of fibrinolytic agents and adjuvant anticoagulant-antiplatelet therapy. The secondary prevention of stroke, along with the renewal of thrombolytic and anticoagulant therapy seems to be an other major area of new approach to antithrombotic therapy. The reocclusion and restenosis of coronary arteries means the most difficult issue and task for antithrombotic treatment modalities. These requirements accelerated the development of novel antithrombotic agents, the disintegrin family, the monoclonals directed against platelet adhesion and aggregation, the application of hirudin and its analogs and new generation of thrombolytic agents. Combined and sequential administration of different antithrombotic agents receives growing attention and seems also to be promising.